2007 Annual Report - The Wistar Institute

Transcription

MAKING
AN
IMPACT
WISTAR SCIENCE
IN THE WORLD
A N N UA L R E P O RT
20
07
Products developed from Wistar science are
protecting the lives of children and adults in
the United States and across the globe.
E
very lifesaving medical advance – every new
medicine, vaccine, or diagnostic test – starts
with a question. How can this disease be treated?
How can we protect against infection by this
virus? How can we detect this illness sooner?
Questions like these drive the work of the
scientists at The Wistar Institute. But finding
answers is just the first step in helping people
to live longer, healthier lives. This is the story of
how Wistar’s scientific breakthroughs have
touched lives all over the world – and the exciting
research that offers new hope for the future.
FROM THE
PRESIDENT
C
hances are that Wistar science has touched your life.
The “MMR” shot you received as a toddler included Wistar’s vaccine against rubella, along
with vaccines against measles and mumps. Thanks in part to Wistar, people living in the United
States and other industrialized nations have little to fear from rabies. And babies born today in
the United States and many other countries will receive a rotavirus vaccine co-developed by
Wistar researchers that will protect them from a potentially deadly gastrointestinal illness.
Wistar’s focus on cancer research has contributed to new and better cancer drugs, as well as a
diagnostic test for breast cancer patients. Therapies based on Wistar’s work are showing promise
in the treatment of other serious diseases as well. The impact of Wistar’s research has been felt
worldwide – in lives saved, suffering avoided, and knowledge gained.
Wistar is dedicated to basic research – investigation driven by a researcher’s interest in a
fundamental scientific question. But Wistar also works to ensure that its scientific breakthroughs
benefit people in need, from a child facing disease in a developing country to a cancer patient
desperate for better treatments.
That’s why the Institute has been partnering for decades with biotechnology and pharmaceutical
companies that can turn its scientific advances into products such as vaccines, medicines, and
diagnostic tests.
Wistar’s efforts to commercialize its inventions produce other benefits as well. Through my
work with the CEO Council for Growth, an affiliate of the Greater Philadelphia Chamber of
Commerce, I have come to appreciate the critical role of technology transfer – the process of
moving a discovery from a laboratory into commercial development – in growing the economy.
In fact, a recent report, commissioned by the council, identified technology transfer as the key
to Philadelphia realizing its potential as one of the nation’s great centers of economic development.
Commercialization activities can generate start-up companies, attract venture capital investment,
and stimulate job growth.
Even more importantly, Wistar’s research contributes to another vital resource: knowledge.
Our scientists distribute their findings through conferences and publications, contributing
immeasurably to the work of other researchers in academic and industry labs.
None of this progress would be possible without the support of the many generous Wistar
friends and donors who recognize the importance of the Institute’s mission and embrace it as
their own.
In these pages, you will learn how Wistar’s research has improved public health. You will read
about the dedicated Wistar scientists who are making inroads in the battle against deadly
diseases. You will meet the people who are making a difference in the lives of others, both
inside the lab and out. The vision, dedication, and determination of these individuals will
continue to lead us to new discoveries – and new hope.
Russel E. Kaufman, M.D.
President and CEO
TABLE OF
CONTENTS
Journey of a Discovery: Working to Benefit Public Health . . . . . . . 4
In the Making: An Early Warning of Lung Cancer . . . . . . . . . . . . . . 6
Looking Back: A Legacy of Impact . . . . . . . . . . . . . . . . . . . . . . . . . 8
On the Horizon: Targeting a Killer Enzyme . . . . . . . . . . . . . . . . . . 10
The Year in Review: Scientific Highlights . . . . . . . . . . . . . . . . . . .12
The Year in Review: The Institute at a Glance . . . . . . . . . . . . . . . .15
Looking Ahead: Finding New Hope Against Cancer . . . . . . . . . . . .16
Letter from the Chair . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .19
Cumulative Giving . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Leroy Kean: Investing in Results . . . . . . . . . . . . . . . . . . . . . . . . 21
Annual Giving . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Rich Beston: A Survivor’s Story . . . . . . . . . . . . . . . . . . . . . . . . . 25
Scientific Staff . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
Administrative Staff . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Volunteer Leadership . . . . . . . . . . . . . . . . . . . . . . . . . inside back cover
JOURNEY
OF A
DISCOVERY
W O R K I N G T O B E N E F I T P U B L I C H E A LT H
W
WISTAR WORKS TO MAKE SURE ITS SCIENTIFIC ADVANCES BENEFIT THOSE IN
NEED—AND THAT TAKES FUNDING, PERSISTENCE, AND COLLABORATION.
istar’s mission is to improve global public health through its scientific achievements. But a
discovery that takes place in a Wistar laboratory is just the first step in that process.
Long before many peer organizations, Wistar began to seek out industry partners who could
develop the Institute’s research into medicines, vaccines, and diagnostic tests that could benefit
the public.
“We want our scientific advances to improve the health of people worldwide, and we have a
proud track record of making that happen,” says Russel E. Kaufman, M.D., Wistar’s president
and CEO. “We make it a priority to get our inventions into the commercial sector so they can
benefit the people who really need them.”
From the lab to the clinic
The path from the laboratory to your doctor’s office or medicine cabinet begins with an idea that
a scientist wants to pursue. At this stage, funding is crucial. Without support from the government,
foundations, and private donors, even the most promising project cannot get off the ground.
Once scientists receive funding, begin their experiments, and gather results, the process of
transforming research advances into new products can still take many years.
“When you’re talking about early-stage research becoming a product in the pharmaceutical or
biotechnology area, there is a huge lag,” says Meryle J. Melnicoff, Ph.D., director of business
development at Wistar. “That’s one of the reasons we need to support early-stage research.
It takes a lot of years, a lot of hard work, and a lot of money to bring these things to the market.”
Take the rotavirus vaccine co-developed at Wistar. Research on the project began in the 1980s,
but the vaccine wasn’t approved for use until 2006. (See the timeline on pullout pages at
right.) That “lag” occurred in part because of the need to conduct extensive safety and efficacy
studies on the vaccine.
The journey of a discovery is also a story of collaboration. After Wistar researchers make discoveries
that have the potential to help people, the Institute partners with organizations such as pharmaceutical and biotechnology companies that have the resources and expertise to further
develop the technology and bring it to market.
“Our commercial partners play an essential role in delivering the benefits of our research to
the public,” Melnicoff says. “We work actively to build and sustain these relationships so that
our research has the greatest possible impact.”
4
ANNUAL REPORT 2007
FA S T
FACTS
• Funding from the government,
foundations, and private donors
helps research projects get off
the ground.
• Wistar was a pioneer in working
with industry to deliver the benefits
of research to the public.
• Developing a research discovery
into a new drug, vaccine, or
diagnostic test can take 10 to
and
ex-smoker s
20 years or longer.
• Collaborations between Wistar
and industry help to drive regional
economic growth by creating jobs.
< < LIFT PAGE FOR TIMELINE.
in the
United States.”
ROTAVIRUS
BIRTH OF A VACCINE
A S T O RY O F PAT I E N C E A N D PA RT N E R S H I P
DEVELOPING A SCIENTIFIC ADVANCE INTO A NEW DRUG, VACCINE, OR DIAGNOSTIC
TEST CAN TAKE 10 TO 20 YEARS OR LONGER. THAT TIME IS SPENT ON RESEARCH,
COLLABORATION, AND TESTING. THE ROTAVIRUS VACCINE CO-DEVELOPED AT WISTAR
WAS NO EXCEPTION.
Wistar scientists Stanley A.
Plotkin, M.D., and H. Fred
Clark, D.V.M., Ph.D., begin
research on a rotavirus
vaccine. They are joined
by Paul A. Offit, M.D., of
Children’s Hospital of
Philadelphia, launching a
Wistar/CHOP collaboration
that continues throughout
the research project.
H. Fred Clark, D.V.M., Ph.D., right,
Wistar adjunct professor,
research professor of pediatrics at
Children’s Hospital of Philadelphia
Wistar files the first patent
application on a promising
early vaccine prototype.
Wistar and CHOP partner
with a major pharmaceutical
company to continue clinical
development of the vaccine.
Stanley A. Plotkin, M.D.,
Wistar professor emeritus
. 1991.
. 1985.
. 1980.
Paul A. Offit, M.D., left, Wistar adjunct
professor, chief of infectious diseases at
ABOUT
ROTAVIRUS
Rotavirus causes severe dehydration illness in infants and
young children. It infects virtually all American children
by the time they reach age 5, causing some 250,000 emergency room visits and 70,000 hospitalizations annually. In
the developing world, where medical facilities are limited,
the infection kills 600,000 infants and children each year.
In addition to being widely
used in the United States,
the rotavirus vaccine has
been launched in 47 other
nations, including several
developing countries. The
vaccine has the potential to
save millions of lives in
coming years.
. 2008.
The rotavirus vaccine is
approved for use by the
FDA and becomes part of
the recommended vaccine
schedule for all U.S. babies.
. 2006.
After the vaccine is proven
safe and effective, the pharmaceutical company
applies to the Food and
Drug Administration for
approval to sell the vaccine
in the United States.
. 2005.
. 2001.
Major clinical trials are
launched to assess the
vaccine’s safety and efficacy.
In the largest vaccine trial
ever performed by a pharmaceutical company, the
vaccine is tested in 70,000
children in 11 countries
under close medical
supervision.
IN THE
MAKING
A N E A R LY WA R N I N G O F L U N G C A N C E R
L
LOUISE SHOWE’S NEW BLOOD TEST FOR LUNG CANCER AIMS TO DETECT THE DEADLY
DISEASE MUCH SOONER, SAVING COUNTLESS LIVES.
ung cancer is the top cancer killer, claiming more lives than breast cancer, prostate cancer, and
colon cancer combined. That’s because by the time it is diagnosed, the disease usually has
advanced so far that treatment options are limited and survival rates much lower than for other
forms of cancer.
More than 200,000 new cases of lung cancer are diagnosed in the United States each year.
Eighty-five to 90 percent of them occur among the country’s estimated 45 million smokers.
“Clearly, there’s a need to serve this at-risk population,” says Louise C. Showe, Ph.D., a professor
in Wistar’s Molecular and Cellular Oncogenesis Program, “because there’s a huge cost in health
care and personal pain and suffering.”
Showe and her colleagues believe they’ve found a way to detect lung cancer in its early stages,
which would save countless lives.
The researchers compared the activity of 25,000 genes in blood samples from lung cancer
patients to the activity of the same genes in a control group of patients with smoking-related
lung disease, but no cancer. They identified a group of just 24 genes that Showe thinks can be
the basis for a new, noninvasive diagnostic test. They have developed a prototype blood test
that can diagnose early-stage lung cancer with nearly 90 percent accuracy.
Meeting a need
Showe believes that a test like the one she is developing is sorely needed. Early detection
programs, which have helped to lower deaths from breast cancer, colon cancer, and prostate
cancer over the past 15 years, have been slow in coming for lung cancer.
“There is an attitude that people with lung cancer have put themselves at risk, and that, as a
result, they deserve less sympathy – an attitude I can’t really understand,” she says. “Smoking
is an addiction. We do a lot of things we probably shouldn’t do in our lives. We really have to
change this attitude toward lung cancer.”
Showe points out that lung cancer also occurs in nonsmokers; in fact, 10 to 15 percent of lung
cancer patients are nonsmokers.
She and her colleagues will continue to develop and refine their test for clinical use. They are
seeking funding to continue their research; early grant support from the Commonwealth
Universal Research Enhancement Program of the Pennsylvania Department of Health recently
ended. “These new technologies are great,” Showe says, “but to do this kind of work and do
it right, you need the funding.”
6
ANNUAL REPORT 2007
FA S T
FACTS
• Lung cancer kills more people
than any other cancer.
• More than 200,000 new cases of
lung cancer are diagnosed in
the United States each year.
• Ten to 15 percent of lung cancer
patients are nonsmokers.
• Three-quarters of lung cancer
patients are diagnosed after the
disease has spread to other
and
ex-smoker s
parts of their body.
• Wistar’s new blood test can
diagnose early-stage lung cancer
with nearly 90 percent accuracy.
in the
United States.”
LOOKING
BACK
A L E G A C Y O F I M PA C T
WISTAR DISCOVERIES HAVE LED TO NUMEROUS PRODUCTS THAT HELP TO PREVENT AND
TREAT DISEASE, SAVING THOUSANDS OF LIVES AND UNTOLD SUFFERING.
F
or nearly 50 years, Wistar has been partnering with companies that translate its scientific
advances into products. These inventions have made an impact worldwide.
Protecting against deadly diseases
Wistar’s success in vaccine development means we have less to fear from several infectious diseases.
• In the 1960s, a Wistar scientist developed a vaccine against rubella, or German measles,
which can cause severe birth defects or miscarriage if it infects a pregnant woman. The
vaccine eradicated the disease in the United States.
• Wistar co-developed a vaccine against rotavirus that was approved in 2006 and recommended
for all U.S. babies. Rotavirus infection kills 600,000 children worldwide each year.
• Wistar’s rabies vaccines for humans and wildlife have helped to make the fatal disease a rarity
in the United States and most other countries.
• The Institute makes its rabies and rubella vaccines available to developing nations at a low
cost to help these countries provide the vaccines to their populations.
Paving the way for new cancer drugs
Wistar research has furthered the understanding of cancer and the development of new treatments.
• Wistar’s research into the biochemical pathways that regulate cancer cell growth laid the
groundwork for a new class of drugs that selectively target cancer cells, sparing patients
the side effects of traditional chemotherapy.
Basic research: the benefit of new hope
The basic research conducted at Wistar, which explores fundamental scientific questions, can
produce unanticipated benefits.
• Twenty years ago, Wistar scientists identified the IL-12 protein. Early tests of the protein
for cancer treatment were not successful, but today, IL-12-based treatments are showing
great promise for the treatment of autoimmune diseases such as multiple sclerosis and psoriasis.
• The Bcl-2 gene, discovered by Wistar scientists, was initially targeted as a cancer treatment.
Today, the gene is part of a diagnostic test that helps to predict whether breast cancer will
recur and helps patients and doctors to select treatment plans.
• In 1978, Institute scientists made antibodies against a type of cancer cell for use in their
research. Today, those antibodies are used worldwide by researchers studying embryonic
stem cells, which may be helpful in treating and regenerating diseased organs.
“When you’re doing basic research, you don’t know what the impact is going to be 10, 20 years
down the road,” says Meryle J. Melnicoff, Ph.D., Wistar’s director of business development. “As
our scientists publish their findings, other researchers build on that knowledge, and the impact
of that is huge.”
8
ANNUAL REPORT 2007
FA S T
FACTS
• Wistar developed or co-developed
vaccines for German measles,
rabies, and rotavirus.
• Research by Wistar scientists
paved the way for new cancer
treatments with fewer side effects.
• Companies are developing
treatments for diseases such as
multiple sclerosis and psoriasis
that are based on Wistar research.
• Wistar’s work in genetics
contributed to a test that helps
breast cancer patients select the
best treatment.
ON THE
HORIZON
TA R G E T I N G A K I L L E R E N Z Y M E
A
EMMANUEL SKORDALAKES’S DECODING OF A CRITICAL REGION OF THE TELOMERASE
MOLECULE COULD LEAD TO TARGETED NEW CANCER THERAPIES.
s a cancer researcher at Wistar, Emmanuel Skordalakes, Ph.D., has a personal investment in the
search for a cure.
“Cancer has been very important to me,” says Skordalakes, an assistant professor in the Gene
Expression and Regulation Program. “I’ve had relatives die of cancer. If we do find something
that can help people, it will be extremely important. It’ll have a huge impact.”
Skordalakes’s investment has already paid dividends. Last year, he and his research team deciphered
the three-dimensional structure of a key region of telomerase (“tuh-lom-uh-reys”), an enzyme
whose inappropriate activation plays a huge role in cancer’s development.
“Telomerase is one of the most important targets – if not the most important – for cancer therapies
right now,” he says. “Between 80 and 90 percent of human tumors have very high levels of
activity of this enzyme. It’s universal; it’s not specific to one cancer.”
Besides being associated with cancer, telomerase is essential for normal cell division and survival.
Its usual role is to add multiple repeats of short lengths of DNA, called telomeres, to the ends
of chromosomes, preventing damage and the loss of genetic information during DNA replication.
It performs this critical service in developing embryos and in a few specialized cell lines,
including embryonic stem cells.
Deciphering a structure
In normal adult cells, telomerase is switched off almost entirely to prevent the dangers of runaway
cell proliferation. But cancer cells often regain the ability to produce the enzyme, permitting
them to replicate indefinitely. Though scientists have sought ways to inhibit telomerase, a lack
of information on its structure has hindered progress.
“We’ve decoded one part of the enzyme that is essential for its function,” Skordalakes notes.
“That could turn out to be a very useful drug target.”
His work holds promise because telomerase is active almost exclusively in cancer cells. A cancer
therapy targeting telomerase would likely not produce side effects because it wouldn’t attack
normal cells – and it would be universal to all cancers.
Because telomerase also plays a role in normal aging, Skordalakes’s research holds potential for
the development of anti-aging treatments as well.
Skordalakes is hopeful that within a year or two, he may decode the structure of the entire
enzyme, greatly expanding the opportunities for developing a new class of cancer drugs. “We’re
in good shape,” he says. “We have something on our hands that could turn out to be very useful.”
10
ANNUAL REPORT 2007
FA S T
FACTS
• Telomerase is active in 80 to 90
percent of human tumors.
• Deactivating telomerase would
cause cells to cease dividing,
killing the cancer.
• Wistar scientists have decoded
the three-dimensional structure
of an important region of
and
telomerase; now they’re focused
on the entire enzyme.
ex-smoker s
• Wistar’s research on telomerase
could lead to new cancer therapies
that are low on side effects and
in the
universal to all cancers.
United States.”
THE YEAR IN
REVIEW:
SCIENTIFIC HIGHLIGHTS
RESEARCH ADVANCES FROM WISTAR LABS
COMPONENT OF NIACIN MAY POINT THE WAY TO ANTI-AGING DRUGS
A family of enzymes called sirtuins can dramatically extend life in organisms as diverse as
yeast, worms, and flies. They may also be able to control age-associated metabolic disorders,
including obesity and type II diabetes.
A study from professor Ronen Marmorstein, Ph.D., and his colleagues points to a strategy for
activating sirtuins to unleash their anti-aging powers. A report on the research appeared in
February in Molecular Cell.
The Wistar team demonstrated that a component of the common vitamin B3, known as niacin,
binds to a site on the sirtuin molecule to inhibit its activity. This observation suggests that
drugs designed to prevent the vitamin B3 component, nicotinamide, from binding at this site
could activate sirtuins.
“Many drugs have unwanted side effects because in addition to the intended target, the drugs
also hit other biologically active molecules that you don’t want to affect,” Marmorstein says.
“This nicotinamide-binding site we’ve identified appears to be unique to the sirtuins, so that if
we’re able to design a molecule to target it, it should be very specific for these sirtuin molecules.”
MicroRNA EDITING HAS IMPLICATIONS FOR VARIETY OF HEALTH ISSUES
Tiny molecules called microRNAs can effectively silence sometimes large sets of genes. They
do this by binding to and neutralizing another form of RNA called messenger RNA, responsible
for conveying the information from genes to the cellular machinery that uses that information
to create proteins, the building blocks of the body. Several hundred species of microRNAs have been
identified to date, and increasingly they are being seen as vitally important players in regulating
the genome.
A recent study by professor Kazuko Nishikura, Ph.D., and her colleagues shows that these
microRNAs can undergo a kind of molecular editing with significant physiological consequences.
A single substitution in their sequence can redirect microRNAs to target and silence entirely
different sets of genes from their unedited counterparts. Further, errors in the editing can lead
to serious health problems. The team’s findings appeared in February in Science.
To explore the ramifications of microRNA editing in depth, the researchers chose one potentially
affected gene at random. As it turned out, the gene they selected codes for an enzyme involved
in synthesizing uric acid. If levels of the enzyme are poorly regulated, a number of health
problems can arise, from gout to deafness. The findings suggest that a number of other as-yet
unidentified disorders may also have their roots in microRNA editing.
12
ANNUAL REPORT 2007
STUDY FINDS ALTERED IMMUNE RESPONSE TO CHRONIC INFECTION
After a viral infection, a small percentage of the T cells that the body generates to kill virus-infected
cells remain to establish long-term immunity. These memory T cells, derived from a family of
immune cells known as CD8 T cells, engage in a self-renewal process that is essential to their
persistence. This ongoing process ensures effective protection against any repeat infection by
the same virus, even decades later.
Scientists at Wistar found that the CD8 T cells generated to fight chronic infections such as HIV
and hepatitis C operate under a different maintenance scheme than the CD8 T cells that become
memory T cells following acute infections. The T cells generated during chronic infection
become dependent on the presence of the virus for their continuation and establish distinct
patterns of cell division.
Understanding how the body’s immune response operates during chronic infections could
help scientists design more effective therapies to fight chronic infections and some tumors,
says assistant professor E. John Wherry, Ph.D. The findings were published in The Journal of
Experimental Medicine in April.
‘INSULATOR’ HELPS SILENCE GENES IN DORMANT HERPES VIRUS
By adulthood, most people have suffered at least one bout of painful cold sores brought on by
the Herpes simplex virus 1, or HSV-1. After the initial infection, the virus usually remains in
the body, hiding out in nearby nerve cells where the victim’s immune defenses cannot reach
it, causing no symptoms.
Wistar scientists discovered a molecular mechanism that keeps HSV-1 activation restricted to a
single gene for months or even years. The researchers have identified an “insulator” – a stretch
of DNA about 800 base pairs long – that serves as a barrier between active and inactive regions
of the virus genome. Base pairs are the nucleotides on each side of the rungs that connect the
strands of the DNA ladder.
“By establishing an insulator in early latency, the Herpes virus can protect this one small region
of the genome from silencing, allowing infected cells to survive,” says associate professor Jumin
Zhou, Ph.D. The findings, which appeared in May in Journal of Virology, mark the first time an
insulator has been identified in a virus.
The study also showed that HSV-1 chromatin is organized in a manner similar to that of the
host chromatin, which may work to the virus’s advantage, says Shelley L. Berger, Ph.D., the
Hilary Koprowski Professor at Wistar. Cromatin is the material that makes up chromosomes.
Knowing what genes the virus uses to hide and re-emerge could give pharmaceutical companies
targets for designing drugs that disrupt those mechanisms.
STUDY DETAILS REGULATION OF VITAL TUMOR SUPPRESSOR GENE
So vital is the tumor suppressor gene p53 in controlling cancer that its dysfunction is linked
to more than half of human cancers. At the same time, the gene’s capacity for shutting down
cell growth, even causing cells to commit suicide if necessary, is so absolute that it must be
tightly regulated to maintain the optimal balance between protecting against cancer and permitting
normal growth.
ANNUAL REPORT 2007
13
THE YEAR IN
REVIEW:
S C I E N T I F I C H I G H L I G H T S continued
A study from the laboratory of Shelley L. Berger, Ph.D., the Hilary Koprowski Professor at
Wistar, reveals new levels of subtlety in the body’s management of this all-important gene and
the protein it produces.
When working properly, the protein produced by p53 is responsible for directing cells with
damaged DNA, including cancer cells, to cease dividing until the damage is repaired. If repairs
cannot be made, the protein commands the cells to self-destruct.
Berger’s experiments show that, while the addition of a specific molecule at a site on the p53
protein prevents it from acting, the addition of a second copy of the same molecule at the same
site reverses the effect, sending the protein into action. Further, removal of the second copy
returns the protein to its repressed state. A report on the study appeared in September in Nature.
VIRUS USED TO CREATE HIV VACCINES IMPAIRS IMMUNE RESPONSE
Efforts to create an HIV vaccine have hinged on the use of viruses as carriers for selected
elements of the HIV virus. Recently, evidence has emerged that some viral vector systems may
undermine the immune system and should not be used for vaccine development.
A study from the laboratory of professor Hildegund C.J. Ertl, M.D., provides strong support for
the idea that some viral-vector vaccines may cause more harm than good.
The findings show that an HIV vaccine construct incorporating one of these viruses, called
adeno-associated virus, or AAV, directly interferes with the immune response to the HIV virus.
Specifically, while it induces HIV-specific T cells, as intended, those cells are functionally impaired
in important ways.
“AAV vaccines against HIV may do more harm than good by robbing people of their natural
immune response to HIV,” Ertl says. A report on the study was published in November in
Journal of Clinical Investigation.
HIV VACCINE FUNDED FOR CLINICAL DEVELOPMENT
An HIV vaccine created in the laboratory of Hildegund C.J. Ertl, M.D., received $13.3 million
in funding over five years for clinical development aimed at moving the vaccine into human
clinical trials. Wistar scientists will collaborate on the project with researchers at Emory
University, the University of Pennsylvania, Harvard School of Public Health, MRC/UVRI
Uganda Research Unit, and the National Institute for Communicable Diseases in South Africa.
Many vaccines currently in development are based on modified human adenoviruses, known
as vectors, which incorporate genetic elements from target pathogens to stimulate a protective
immune response to those pathogens.
These vaccines can work well, but many people receiving them will have pre-existing immunity
to the human viruses upon which they are based, largely negating the vaccines’ effectiveness.
To circumvent this potential difficulty, the team at Wistar developed a series of vaccine vectors
based on chimpanzee adenovirus strains, which possess the immunological strengths of human
adenoviruses without their drawbacks.
14
ANNUAL REPORT 2007
THE YEAR IN
REVIEW:
T H E I N S T I T U T E AT A G L A N C E
STAFF
SOURCES OF FUNDS
Total number of employees
330
Number of laboratories
31
Number of postdoctoral fellows
63
Number of predoctoral trainees
28
Number of visiting scientists
21
Number of countries of origin represented
30
(Algeria, Argentina, Australia, Austria, Brazil, Canada, China, Croatia,
Ireland, France, Germany, Ghana, Greece, Hungary, India, Iran, Israel,
Japan, Korea, Malaysia, Peru, Poland, Qatar, Romania, Russia, Singapore,
Trinidad, United Kingdom, United States, Vietnam)
Federal grant funding
Foundation and other private funding
State funding
Corporate-sponsored research
Unrestricted contributions
Technology transfer
Total return from invested funds
TOTA L
$26,900,000
$4,970,000
$3,668,000
$284,000
$1,534,000
$8,033,000
$8,096,000
$53,485,000
50%
9%
7%
1%
3%
15%
15%
100%
$30,865,000
$7,867,000
$5,503,000
$397,000
$3,491,000
$48,123,000
65%
16%
11%
1%
7%
100%
USES OF FUNDS
U.S. PATENTS ISSUED
Compositions and Methods to Enhance Sensitivity of Cancer Cells to
Mitotic Stress, Thanos Halazonetis, U.S. Patent No. 7,176,293
Peptides and Peptidomimetics with Structural Similarity to Human p53
that Activate p53 Function, Thanos Halazonetis, U.S. Patent No. 7,189,801
Methods for Detecting DNA Damage and Screening for Cancer Therapeutics,
Thanos Halazonetis, U.S. Patent No. 7,217,532
Organotypic Intestinal Culture and Methods of Use Thereof, Meenhard
Herlyn, U.S. Patent No. 7,217,570
RESEARCH CENTERS
The Albert R. Taxin Brain Tumor Research Center
The Center for Systems and Computational Biology
The Robert A. Fox Structural Biology Center
The Wistar Institute Cancer Canter
The Wistar Institute Vaccine Center
Direct research
Administration and laboratory services
Operation and maintenance of plant
Library operation
Depreciation of capital assets
TOTA L
$30,865,000 (65%)
Direct research
$7,867,000 (16%)
Administration and
laboratory services
$5,503,000 (11%)
Operation and
maintenance of plant
$397,000 (1%)
Library operation
$3,491,000 (7%)
Depreciation of capital assets
SHARED FACILITIES
Animal Facility
Bioinformatics Facility
Flow Cytometry Facility
Genomics Facility
Histotechnology Facility
Hybridoma Facility
Microscopy Facility
Mouse Genetics Facility
Protein Expression Facility
Proteomics Facility
Research Supply Facility
ANNUAL REPORT 2007
15
LOOKING
AHEAD
FINDING NEW HOPE AGAINST CANCER
EARLY-STAGE RESEARCH IS ABOUT POSSIBILITIES – FRESH IDEAS THAT MAY CREATE
NEW HOPE AGAINST ILLNESS.
E
very day, Wistar scientists explore the unknown with creativity and dedication, following
where their research leads. This kind of investigation can change our understanding of disease,
opening up entirely new approaches to treating it. Read on to learn more about exciting early-stage
cancer research projects at Wistar.
DESIGNING BETTER BRAIN TUMOR THERAPIES
Brain tumors can be devastating diseases for patients and their families. Too often, treatments
fail – and even successful treatments may cause severe side effects, from cognitive deficits to
balance problems.
Assistant professor Nadia Dahmane, Ph.D., is collaborating with Jeffrey Winkler, Ph.D., at
the University of Pennsylvania to design new brain tumor therapies. Their work focuses on a
molecular pathway that plays an important role in brain development. When disturbed, this
pathway may give rise to brain tumors.
Cancers associated with the pathway include medulloblastoma, the most common brain
tumor in children, and glioblastoma multiforme, an aggressive and especially deadly brain
tumor that primarily affects adults over 50.
“We need to find new treatments to give patients better odds of surviving and reduce the side
effects,” Dahmane says.
HARNESSING THE IMMUNE SYSTEM TO FIGHT LUNG CANCER
Lung cancer is the deadliest cancer, causing more deaths each year than breast cancer, prostate
cancer, and colon cancer combined. The need for better treatment approaches is urgent.
Working together, Wistar assistant professors Joseph Kissil, Ph.D., and E. John Wherry, Ph.D.,
are aiming to harness the immune system to help fight the disease.
Kissil has developed a mouse model that enables researchers to study the most common
type of human lung cancer, while Wherry is exploring how immune cells called T cells become
“exhausted” and unable to perform effectively. The goal: to find a way to boost the immune
response to the disease.
“We each bring different expertise, which allows us to look at lung cancer in a new way,” Kissil
says. Wherry adds: “The collaboration is enabling us to do work that neither of us could do alone.”
UNDERSTANDING BREAST CANCER METASTASIS
16
When diagnosed early, breast cancer can often be treated successfully. But when breast cancer
spreads to other tissues – a process called metastasis – it becomes much harder to treat.
Assistant professor Qihong Huang, M.D., Ph.D., is working to find the causes of breast cancer
metastasis in order to develop better therapies.
“Metastasis is the major cause of death in cancer patients,” Huang says. “That’s true not
just for breast cancer but for cancers in general. If we can understand how metastasis happens,
we can try to develop new drugs to stop the process.”
Huang is studying the human genome, looking for promoters and suppressors of breast
cancer metastasis. Already he has identified one target that may help in the early diagnosis of
metastatic breast cancer.
ANNUAL REPORT 2007
Qihong Huang, M.D., Ph.D
Nadia Dahmane, Ph.D.
E. John Wherry, Ph.D., left, and Joseph Kissil, Ph.D.
“Wistar laboratories are the birthplace
of new knowledge and new hope.”
MESSAGE
FROM THE
CHAIR
W
istar’s scientists are among the most talented, creative, and dedicated in the world. They spend
countless hours in the lab, working on experiments that can take years. Their motivation
through it all is to gain knowledge that will save lives. Over the decades, these efforts have paid
off in a rich history of Wistar discoveries that have improved the health of people worldwide.
Not all of us can be scientists, but those of us who care deeply about this vital work still have
an important role to play. Those who choose to support Wistar with their time, leadership, and
financial contributions are essential to the Institute’s progress, especially now. Grant funding
levels at the National Institutes of Health, Wistar’s primary research sponsor, have been flat or
in decline for several years. Without sufficient financial resources, research projects will not
get off the ground.
Wistar’s board of trustees provides excellent examples of the leadership that keeps the Institute
strong – people like Hal Davis, a longtime Wistar supporter who received the Wistar Award in
October, and Ruth Patrick, Ph.D., a pioneering biologist who has served on the board for more
than three decades. In the past year, we welcomed three new members who will continue this
proud tradition of service: Dani Paul Bolognesi, Ph.D.; George J. Vergis, Ph.D.; and Dan W.
Matthias. We also prepared to bid farewell to two valued members: Susan R. Sullivan and Ira
M. Lubert, who will remain close friends of the Institute.
Wistar also established the Leadership Council to provide even more opportunities for energetic
community leaders to help the Institute forge new relationships and plan for its future.
Each of us who supports Wistar can take pride in our contribution, no matter how small or large.
Wistar laboratories are the birthplace of new knowledge and new hope. The research that goes
on there is vital if we are to make headway against the diseases that claim so many lives today –
to understand the mysteries of cancer development, tumor progression, and HIV infection. These
are the problems that Wistar scientists are grappling with, and making progress toward solving.
I’d like to thank everyone who participates in these noble efforts. If you don’t yet support research
at Wistar, please consider joining us as we pursue today’s discoveries and tomorrow’s cures.
Brian H. Dovey
Chair, Board of Trustees
ANNUAL REPORT 2007
19
CUMULATIVE
GIVING
PRESIDENT’S COUNCIL
($ 1 MILLION and over)
American Cancer Society
Arthritis Foundation
Commonwealth of Pennsylvania
Mr. and Mrs. Harold M. Davis
Mr. and Mrs. Robert A. Fox
Dr. Herbert Kean and The
Honorable Joyce Kean
F. M. Kirby Foundation, Inc.
G. Harold & Leila Y. Mathers
Charitable Foundation
National Science Foundation
The Pew Charitable Trusts
Philadelphia Health Care Trust
W.W. Smith Charitable Trust
--------------------------------------------------------------
ISAAC WISTAR SOCIETY
($500,000 and over)
Anonymous
The Breast Cancer Research Foundation
Mr. Ira Brind
The Ellison Medical Foundation
Edward Mallinckrodt, Jr. Foundation
The Elsa U. Pardee Foundation
The Philadelphia Foundation
Fannie E. Rippel Foundation
The V Foundation for Cancer Research
20
ANNUAL REPORT 2007
CENTENNIAL SOCIETY
($100,000 and over)
Dr. Miriam & Sheldon G. Adelson Charitable Trust
American Health Assistance Foundation
American Institute for Cancer Research
Anonymous
The Arcadia Foundation
Asthma and Allergy Foundation of America
Arnold and Mabel Beckman Foundation
Mr. and Mrs.Vincent G. Bell, Jr.
Mr. and Mrs. Robert S. Blank
Breast Cancer Alliance, Inc.
The Campbell Foundation
Cancer Research and Prevention Foundation
Cancer Research Institute
CaP Cure
Jose Carreras International Leukemia Foundation
CLAWS Foundation
Concern Foundation for Cancer Research
Cystic Fibrosis Foundation
Mr. Arthur Dantchik
Meyer and Stephanie Eglin Foundation
The Emerald Foundation
First Union National Bank
Charlotte Geyer Foundation
GlaxoSmithKline
Irving A. Hansen Memorial Foundation
The Hassel Foundation
Mrs. Beverly Hattersley
Mr. and Mrs. Roger S. Hillas
B.Wayne Hughes
Jewish Federation of Greater Philadelphia
Max Kade Foundation
Katie’s Kids for the Cure
Mr. Leroy E. Kean
Mrs. Patricia Kind
Susan G. Komen Breast Cancer Foundation
Mr. and Mrs. Ronald J. Kozich
The Kresge Foundation
Leukemia Society of America, Inc.
Mr. Ira M. Lubert
Mrs. Louis C. Madeira IV
The Maxfield Foundation
The McLean Contributionship
The Benjamin and Mary Siddons Measey Foundation
Mrs. Martha S. Miller
Mr. and Mrs. Marc Miller
The Warren V. Musser Foundation
National Medical Technology Testbed
National Multiple Sclerosis Society
Mrs. Agnes Eckhardt Nixon
Albert Ominsky, Esquire
Robert Leet & Clara Guthrie Patterson Trust
The William Penn Foundation
Gustavus & Louise Pfeiffer Research Foundation
Mr. and Mrs. S. Edward Rhoads
Mr. and Mrs. Gerald B. Rorer
Mr. and Mrs. Lester Rosenfeld
Mr. and Mrs. Harold G. Schaeffer
Ms. Emily Brown Shields
Sibley Memorial Hospital
Mr. and Mrs. Edward Sickles
The Hoxie Harrison Smith Foundation
The Mary L. Smith Charitable Lead Trust
The Susan R. and John W. Sullivan Foundation
Mr. and Mrs. John W. Sullivan
Mrs. Doris R. Taxin
Howard S. Turner, Ph.D.
United Way of Southeastern Pennsylvania
Mr. and Mrs. David V.Wachs
Samuel Waxman Cancer Research Foundation
Mr. C. Cresson Wistar
The Wistar Science Trust Fund
PATRON’S SOCIETY
($50,000 and over)
Accelerate Brain Cancer Cure
American Heart Association
Anonymous
Barra Foundation, Inc.
Ben Franklin Technology Center
Mr. Peter A. Benoliel and Ms. Willo Carey
Mr. and Mrs. Ian J. Berg
The CFIDS Association Inc.
Mr. and Mrs. Brian H. Dovey
The Dovey Family Foundation
Mrs. Stephanie S. Eglin
Federation Foundation of Greater Philadelphia
Mr. and Mrs. Joseph M. Field
Friends of The Wistar Institute
Mr. John Kinderman
Leukemia Research Foundation
John M. Lloyd Foundation
Mellon Financial Services
Mr. and Mrs. Alan B. Miller
National Dairy Council
Pharmaceutical Research and Manufacturers
of America Foundation
Philadelphia Heart Institute
Mr. and Mrs. Seymour S. Preston III
Procter & Gamble Company
RAF Industries
Mr. and Mrs. Robert H. Rock
Mrs. Julia Rousso
Mr. Ronald Rubin
Dr. and Mrs. Karl F. Rugart, Jr.
Mary A. H. Rumsey Foundation
sanofi pasteur
The Scholler Foundation
The Charles Spear Charitable Trust
Susquehanna Foundation
Mr. and Mrs. Sylvan M. Tobin
Vanguard Charitable Endowment Program
Wawa Inc.
Daniel Wheeler, Esq. and Ms. Amy Fox
LEROY E. KEAN
I N V E S T I N G I N R E S U LT S
GUARANTOR’S SOCIETY
($10,000 and over)
Mr. and Mrs. Robert S. Adelson
Adler Foundation, Inc.
Mr. and Mrs. Robert M. Alper
Alzheimer’s Association, Inc.
American Association for Cancer Research
American-Italian Cancer Foundation
Mr. and Mrs. Robert Angevine
The Annenberg Foundation
Anonymous
Atlantic Real Estate Group
Aventis Pasteur
EV Bell Foundation
Morris S. Bender and Florence H. Bender Foundation
Binswanger
Mr. John K. Binswanger
Mr. and Mrs. Alan D. Bleznak
Old Original Bookbinder’s Restaurant
Brain Tumor Society
The Breast Cancer Fund
Mr. and Mrs. Francis X. Bresnan
Fred J. Brotherton Charitable Foundation
Leonard A. Bruno, M.D.
Buckingham Mountain Foundation
Mr. James D. Troyer and Ms. Kathleen Callan
Louis N. Cassett Foundation
Dr. and Mrs. James Cavanaugh
Cephalon
Mr. and Mrs. Robert E. Chappell
Ms. Stacy Chern and Mr. Ty Wu
Mrs. June H. Chern
Citizens Bank of Pennsylvania
Mrs. John B. Clapham*
Mr. and Mrs. Alvin H. Clemens
The Coca-Cola Foundation
The Philadelphia Coca-Cola Bottling Co.
Mr. and Mrs. Philip Cohen
Comcast Spectacor
Connelly Foundation
Mr. and Mrs. Michael Coslov
Mr. and Mrs. Stephen Allen Cozen
Cozen O'Connor
Linda Creed Breast Cancer Foundation
Mr. David Cutler
Daiichi Pharmaceutical Co., Ltd.
The Eleanor Naylor Dana Charitable Trust
Robert C. Daniels, Esquire
David Cutler Group
Mr. C. Edwin Davis
Mr. and Mrs. Rodney D. Day III
Mr. and Mrs. Francis W. De Serio
William B. Dietrich Foundation
Dolfinger-McMahon Foundation
Eagles Fly for Leukemia
Electric Factory Concerts
Mr. and Mrs. Stanley Elkman
Leroy E. Kean says that he supports Wistar’s lung cancer research for two important
reasons: the urgent need for better treatments and the fact that he can see results.
More people die from lung cancer each year than from any other form of
cancer. Kean lost his wife Lois to the disease in 2002.
“There is still so much we don’t know about lung cancer, such as why
some people are more susceptible to it than others,” he says. “Because of Wistar’s
small size and focus, I can meet the scientists and see directly how my support
is making a difference.”
Kean provided the seed money for Wistar assistant professors Joseph
Kissil, Ph.D., and E. John Wherry, Ph.D., to begin a promising project aimed at
harnessing the immune system to fight lung cancer. (See page 16.) Based on
their early results, they have since won a federal research grant amid stiff
national competition.
“Leroy Kean made an investment in our early-stage research,” Kissil says.
“That was crucial, especially in today’s challenging funding environment.”
“We can’t say enough about the impact of his support,” Wherry adds.
“Without his vision, we couldn’t have gotten this project off the ground.”
*Deceased
After losing his wife to lung cancer, Leroy E. Kean donated funds to
launch a promising lung cancer research project at Wistar.
ANNUAL REPORT 2007
21
CUMULATIVE G I V I N G continued
GUARANTOR’S SOCIETY
($10,000 and over) continued
Mr. Julius W. Erving
The Expedition Inspiration Fund for Breast
Cancer Research
Mr. and Mrs. Jerome M. Feig
Mr. David Feld
Mr. and Mrs. Joseph J. Fenkel
Fisher Scientific
Ms. Sara Jane Fitzpatrick
Fleet Bank
Mr. and Mrs. James W. Fordyce
Mr. and Mrs. Richard J. Fox
The Richard J. Fox Foundation
Mr. and Mrs. Benjamin Frankel
Mr. and Mrs. Stanton H. Friedman
Friedman-French Foundation
The Eugene Garfield Foundation
GBH Foundation
Mr. Joel Gershman and Ms. Elaine Levitt
Ruth Estrin Goldberg Memorial for Cancer Research
Mr. and Mrs. Joseph A. Goldblum
Mr. and Mrs. Bruce A. Goodman
Viola N. Goodrich Irrevocable Trust
Mr. and Mrs. Irwin Govberg
Mr. Joel K. Greenberg and Ms. Marcy Gringlas
Helen D. Groome Beatty Trust
Dr. Jennifer Gross and Mr. Eli A. Gross
Mrs. Samuel M. V. Hamilton
Mr. and Mrs. Brian G. Harrison
Louise A. Havens Foundation for Diabetes Research
& Treatment
Ellen Heber-Katz, Ph.D., and David Sarfatti
Drs. Meenhard and Dorothee Herlyn
The Honorable and Mrs. Harris N. Hollin
Mr. and Mrs. Richard M. Horowitz
Howson & Howson, Ltd.
IBEW/NECA
Mr. and Mrs. Ira M. Ingerman
Innisfree Foundation of Bryn Mawr
Invitrogen
Mr. and Mrs. Jerry L. Johnson
Kaplan Pomerantz Schaeffer Foundation
Mr. and Mrs. Harold Katz
Dr. and Mrs. Russel E. Kaufman
Mr. Larry A. Keinath and Ms. Rosemary Spingler
Mr. and Mrs. Joseph Kestenbaum
Keystone Foods Corporation
Mr. and Mrs. Sidney Kimmel
Mr. and Mrs. H. Lewis Klein
Lenore and Howard Klein Foundation
Mrs. Lillian S. Kosloff
Mr. and Mrs. Ronald A. Krancer
KYW-AM 1060
Ladies Auxiliary to the V.F.W.
Mr. and Mrs. Thomas F. Lafferty
Mr. and Mrs. Harvey Lamm
Mr. and Mrs. Mitchell G. Leibovitz
Mr. and Mrs. H. F. Lenfest
Mr. and Mrs. Howard H. Lewis
Harry A. Lieberman Foundation
Mr. and Mrs. Burton S. Lifson
Lisker Foundation
Mr. and Mrs. Herbert Lotman
The Karen and Herbert Lotman Foundation
Ms. Melissa Ludwig and Dr. Frank J. Rauscher III
Lupus Foundation of America, Inc.
Lupus Foundation of Southeastern Pennsylvania, Inc.
Mr. and Mrs. James J. Lynch
Mr. and Mrs. John A. Lynott
Mr. and Mrs. Larry Magid
Mr. Nicholas V. Martell and Ms. Nancy Westin
Merck & Co. Inc.
Merck Research Laboratories
The Merck Society for the Arts & Sciences
Midlantic Bank, N.A.
Mr. Henry S. Miller, Jr. and Mr. Ken Nimblett
Mr. and Mrs. I. Wistar Morris III
MSR Imports
Noreen O’Neill Foundation for Melanoma Research
Oxford Foundation, Inc.
Mr. and Mrs. Timothy P. Pesce
Mr. Carl D. Peterson
Philadelphia Phillies
The PNC Financial Services Group
PRWT Services
Mr. and Mrs. David Pudlin
Quaker Chemical Foundation
Mrs. Diane S. Raynes
Realen Properties
Dr. and Mrs. Donald Vail Rhoads
Mr. and Mrs. William G. Rhoads
Rhone-Poulenc Rorer, Inc.
Martha W. Rogers Charitable Trust
Mr. and Mrs. Marvin J. Rounick
Giovanni Rovera, M.D.
Safeguard Scientifics, Inc.
Mr. and Mrs. George U. Sauter
Mr. and Mrs. Paul J. Schmitt
Mr. Richard A. Scott
SEI Investments Company
Mr. and Mrs. Roy Shapiro
Franz W. Sichel Foundation
Sovereign Bank
David W. Speicher, Ph.D.
Mr. Benjamin Strauss
Mr. and Mrs. Barry E. Tague
Mr. and Mrs. Larry Tanenbaum
Mr. Myles H. Tanenbaum
Mr. and Mrs. Edward Tawil
Mrs. Jean M. Taxin
Robert M. Taxin, D.O.
Mr. and Mrs. Thomas J. Teesdale
Ten Pennies Florist & Decorators
TIAA-CREF Employee Giving Campaign
Mr. and Mrs. Gilbert Tucker
Mr. and Mrs. Kevin M. Tucker
Universal Health Services, Inc.
University of Pennsylvania Alzheimer’s Center
Mr. and Mrs. Richard A. Vermeil
Mr. and Mrs. Morton B. Wapner
Mrs. Barbara R. Washburn
Mr. and Mrs. Larry Weiss
Ms. Monica Polowy Winter
Mrs. Joan H. Wister
Mr. Steven Wynn
Cumulative giving levels reflect gifts since January 1, 1992.
22
ANNUAL REPORT 2007
ANNUAL
GIVING
CASPAR WISTAR SOCIETY
($ 1 MILLION and over)
Philadelphia Health Care Trust
--------------------------------------------------------------------
CENTENNIAL SOCIETY
($100,000 and over)
Dr. Miriam & Sheldon G. Adelson
Charitable Trust
Arnold and Mabel Beckman Foundation
CLAWS Foundation
The Ellison Medical Foundation
F. M. Kirby Foundation, Inc.
March of Dimes Foundation
G. Harold & Leila Y. Mathers Charitable
Foundation
The Elsa U. Pardee Foundation
The Pew Charitable Trusts
Sibley Memorial Hospital
W.W. Smith Charitable Trust
The V Foundation for Cancer Research
Samuel Waxman Cancer Research Foundation
-------------------------------------------------------------------PATRONS
($50,000 and over)
Accelerate Brain Cancer Cure
Mr. Ira Brind
The Emerald Foundation
GUARANTORS
($10,000 and over)
WISTAR FELLOWS SOCIETY
($1,000 and over)
Barra Foundation, Inc.
Mr. and Mrs. Vincent G. Bell, Jr.
Mr. and Mrs. Ian J. Berg
Mr. and Mrs. Robert S. Blank
Mr. and Mrs. Francis X. Bresnan
Mrs. June H. Chern
The Dovey Family Foundation
Mr. and Mrs. Brian H. Dovey
EV Bell Foundation
Mr. and Mrs. Joseph M. Field
The Hassel Foundation
Mr. and Mrs. Joseph A. Goldblum
Mr. Joel K. Greenberg and Ms. Marcy Gringlas
Mr. and Mrs. Brian G. Harrison
The Karen and Herbert Lotman Foundation
Innisfree Foundation of Bryn Mawr
Jewish Federation of Greater Philadelphia
Max Kade Foundation
Mr. and Mrs. H. Lewis Klein
Mr. and Mrs. Ronald A. Krancer
Mr. and Mrs. Herbert Lotman
Pharmaceutical Research and Manufacturers
of America Foundation
Mr. and Mrs. Seymour S. Preston III
PRWT Services
RAF Industries
Realen Properties
Mr. Thomas A. Reynolds III*
Mr. and Mrs. S. Edward Rhoads
Mr. and Mrs. Gerald B. Rorer
Mr. Ronald Rubin
Mr. and Mrs. Harold G. Schaeffer
Mr. and Mrs. Edward Sickles
The Susan R. and John W. Sullivan Foundation
Mr. and Mrs. John W. Sullivan
Susquehanna Foundation
United Way of Southeastern Pennsylvania
Vanguard Charitable Endowment Program
Wawa Inc.
Albert Tire Company
Mr. and Mrs. William A. Albert
ALC Environmental Incorporated
Allentown, Inc.
Alpha Office Supplies
American Financial Realty Trust
American Skin Association
Mrs. Jane T. Andress
Mr. and Mrs. Robert Angevine
The Annenberg Foundation
Atlantic Real Estate Group
Mr. Scott Barsky
Morris S. Bender and Florence H. Bender
Foundation
Mr. Peter A. Benoliel and Ms. Willo Carey
Binswanger
Blank Rome LLP
The Besse & Louis M. Bleznak Foundation
Mr. and Mrs. Kenneth Bleznak
Ms. Joann Burke
Mr. and Mrs. Robert Casciato
Mr. and Mrs. Robert E. Chappell
Dr. Catherine Chern
Ms. Stacy Chern and Mr. Ty Wu
Chester County Community Foundation
Citizens Bank of Pennsylvania
Citizens Charitable Foundation
Mrs. John B. Clapham*
Mr. and Mrs. Norman Cohn
Mr. Stephen J. Colletti
Comcast Spectacor
Concord Advisory Group
Connelly Foundation
Mr. and Mrs. Peter E. Corrado
Mr. and Mrs. Michael Coslov
Cozen O’Connor
Mrs. Margaret F. Cristofalo
CRW Graphics
David Cutler Group
Mr. and Mrs. Rodney D. Day III
Deb Shops, Inc.
Ms. Sylvia Di Bona
Mr. and Mrs. W. Joseph Duckworth
Electric Factory Concerts
Mr. Steve Feig
Mr. and Mrs. Joseph J. Fenkel
Fidelity Charitable Gift Fund
Firstrust Bank
Fishman and Tobin
Mr. and Mrs. P. Richard Frieder
GBH Foundation
Mr. Joel Gershman and Ms. Elaine Levitt
GlaxoSmithKline
Mr. Adam S. Goldman
Dr. and Mrs. Alfred E. Goldman
Greater Philadelphia Chamber of Commerce
Mr. Leroy E. Kean
*Deceased
Mr. Ira M. Lubert
Edward Mallinckrodt, Jr. Foundation
ANNUAL REPORT 2007
23
ANNUAL G I V I N G continued
WISTAR FELLOWS SOCIETY
($1,000 and over) continued
Dr. Jennifer Gross and Mr. Eli A. Gross
Mr. and Mrs. Barry Group
Mr. and Mrs. Richard H. Gwinn
Mrs. Samuel M. V. Hamilton
Mr. and Mrs. Frederick S. Hammer
Hangley Aronchick Segal & Pudlin
Mrs. Beverly Hattersley
Ellen Heber-Katz, Ph.D., and David Sarfatti
Drs. Meenhard and Dorothee Herlyn
Mr. and Mrs. Roger S. Hillas
Mr. and Mrs. George Hirschhorn
Mr. Andrew Hoffman
Mr. and Mrs. Ira M. Ingerman
Kaplan Pomerantz Schaeffer Foundation
Mr. and Mrs. Harold Katz
Dr. and Mrs. Russel E. Kaufman
Dr. Herbert Kean and The Honorable Joyce Kean
Mr. Larry A. Keinath and Ms. Rosemary Spingler
Mr. and Mrs. Robert E. Keith
Keystone Mercy Health Plan
Lenore and Howard Klein Foundation
Ms. Susan S. Kozik
Mr. and Mrs. Thomas F. Lafferty
Mr. and Mrs. Mitchell G. Leibovitz
Mr. and Mrs. Mark Lenet
Mr. and Mrs. H. F. Lenfest
Harry A. Lieberman Foundation
Mr. Harry A. Lieberman
Live Nation
Ms. Denise G. Loughlin
Mr. William Luterman
Mr. and Mrs. James J. Lynch
Mr. and Mrs. Larry Magid
Samuel P. Mandell Foundation
Ms. Carol McMichael
Merck & Co. Inc.
Merrill Lynch & Company
Mr. and Mrs. Alan B. Miller
Mr. and Mrs. William Mutterperl
National Analysts, Inc
Mr. and Mrs. Scott O’Neill
Ruth Patrick, Ph.D.
Mr. and Mrs. Stuart Peltz
Pennsylvania Lumbermens Mutual Insurance
Company
Pepper Hamilton, LLP
Mr. and Mrs. Frank Pesce
Philadelphia Phillies
Dr. and Mrs. Stanley A. Plotkin
Mr. and Mrs. David Pudlin
Radnor Trust
Dr. and Mrs. Frank J. Rauscher III
Realty Landscaping Corporation
Mr. and Mrs. Lawrence S. Reichlin
Dr. and Mrs. Kenneth Scott Resnik
Mr. and Mrs. William G. Rhoads
Riesentoter Region PCA
Rittenhouse Foundation
Mr. and Mrs. Adam Rosenfarb
24
ANNUAL REPORT 2007
Mrs. Julia Rousso
Mr. and Mrs. Seymore Rubin
Mr. and Mrs. Paul J. Schmitt
Mr. and Mrs. Roy Shapiro
Ms. Emily Brown Shields
Franz W. Sichel Foundation
Bernard W. Smalley, Esq.
Ms. Judith E. Soltz and Mr. Richard S. Belas
Sovereign Bank
Tawil Associates
Mr. and Mrs. Edward Tawil
Mrs. Doris R. Taxin
TIAA-CREF Employee Giving Campaign
Ms. Eunice Trevor
Mr. and Mrs. Gilbert Tucker
Mr. Stephen Tustin
U.S. Trust Company, N.A.
Universal Health Services, Inc.
Verizon Pennsylvania, Inc.
Mr. and Mrs. Richard A. Vermeil
Wachovia Bank, N.A.
Mr. and Mrs. Richard L. Weisberg
Mr. and Mrs. Larry Weiss
Mr. and Mrs. Alfred P. West, Jr.
Daniel Wheeler, Esq. and Ms. Amy Fox
ZS&M Wilf Foundation, Inc.
Mr. and Mrs. Mark Wilf
Mr. and Mrs. James B. Wistar
Wolf, Block, Schorr and Solis-Cohen
SPONSOR
($500 and over)
A Ambassador Travel
Mr. and Mrs. Robert S. Adelson
Ms. Karlyn Rosen Aires
Anonymous
Mr. Thomas J. Baldoni
Ms. Joyce C. Barrett
Mr. and Mrs. Henry S. Belber
Mrs. Murray Belman
Mr. and Mrs. Richard F. Biborosch
Mr. and Mrs. Frank G. Binswanger, Jr.
Bollinger
Mr. and Mrs. Fred E. Braemer
Mr. and Mrs. Douglas S. Briggs
The Capital Group Companies Charitable
Foundation
Mr. and Mrs. Cummins Catherwood, Jr.
Mr. James A. Chafoulias
Mr. Jack Cornish
Mr. and Mrs. Edward C. Driscoll
Mr. and Mrs. Leonard Dubin
Mr. and Mrs. Stanley Elkman
Mr. and Mrs. Mack Emanuel
Mr. and Mrs. Michael J. Emmi
Mr. and Mrs. Daniel E. Francis
Mr. and Mrs. Benjamin Frankel
Mr. and Mrs. W. Roderick Gagne
Dr. and Mrs. John H. Goodworth
Mr. and Mrs. Donald C. Graham
Mr. Joseph F. Grusemeyer
Mr. and Mrs. John C. Haas
Mr. and Mrs. Christian M. Hoechst, Jr.
The Honorable and Mrs. Harris N. Hollin
HSA Management Company LLC
WISTAR
HERITAGE
SOCIETY
The Wistar Heritage Society recognizes the
foresight and generosity of individuals who
elect to perpetuate their support of biomedical
research by including the Institute in their
wills or estate plans. Membership is a partnership
for life that offers the promise of discovery of
new treatments and cures for cancer and
other diseases.
Questions regarding membership in the Wistar
Heritage Society should be directed to Wistar’s
Development Office at (215) 898-3930. Members
as of April 11, 2008 are:
Francis X. Bresnan
Ira Brind
June H. Chern
Peter E. Corrado
Harold M. Davis
Julia A. Felton
Dr. Jerome I. Flicker
Dr. and Mrs. Alfred E. Goldman
Meenhard Herlyn, D.V.M.
Dorothee M. Herlyn, D.V.M.
The Honorable Harris N. Hollin
Mrs. Constance Jordan
Miss Rivka Kaestner
Herbert Kean, M.D.
Hilary Koprowski, M.D.
Kurtis L. Meyer
Paula R. Meyer
Marc D. Miller
Martha S. Miller
Sandya Narayanswami, Ph.D.
Elizabeth A. Pesce
Timothy P. Pesce
Lt. Col. Carolyn Reinbold
Karl F. Rugart, Jr., M.D.
Emily Brown Shields
Family of Stephen M. Shoyer
Ann G. Sickles
Edward Sickles
Mrs. Joan H. Wister
RICH BESTON
Mrs. Klaus Hummeler
Mr. and Mrs. Alan D. Isen
Mr. and Mrs. James P. Kane
Bonnie T. Kay, Ph.D.
Mr. and Mrs. Jon S. Kean
Keystone Industries
Mrs. Lillian S. Kosloff
Mr. and Mrs. Dean W. Laskaris
Mr. and Mrs. Christopher Loomis
Mr. and Mrs. Gerard J. Lynott, Jr.
Mr. and Mrs. Dan Matthias
Mr. Graham and Dr. Susan McDonald
Mr. and Mrs. Sam S. McKeel
Mr. and Mrs. Gerald Moller
Mr. and Mrs. Dennis R. Moran
Mr. and Mrs. John Mullen
Mr. and Mrs. Anthony A. Nichols
Dr. Paul Allan Offit
Mr. and Mrs. Jeremiah P. O’Grady
Mr. and Mrs. Robert Oppenheimer
Agneta S. Orleans
Mr. Jeffrey P. Orleans
Mr. and Mrs. Adolf A. Paier, Jr.
Mr. and Mrs. Peter F. Pecoraio
Mrs. Asa W. Potts
George C. Prendergast, Ph.D.
Provincial Foundation
The Honorable Marjorie O. Rendell
Mr. and Mrs. Robert H. Rock
Mr. Ed Rogers
Dr. and Mrs. Harvey Rosen
Mr. and Mrs. Martin Rosen
Eileen Rosenau and Jerome Kurtz
Mr. Wayne D. Rowland and Ms. Denise
DiPangrazio
Mr. and Mrs. William Schade
Mr. and Mrs. K. George Schoeppner
Mr. David W. Schusler
Mr. Richard A. Scott
Mr. and Mrs. Richard Seitchik
Mr. and Mrs. A. Leonard Senker
Mr. and Mrs. Howard A. Silverman
Mr. and Mrs. Joseph V. Somers
Mr. and Mrs. Harold A. Sorgenti
Mr. and Mrs. David L. Spooner
Mr. and Mrs. Paul T. Stefanik
Stiletto
Mr. and Mrs. James C. Vanderwaal
Wilkie Chevrolet/Buick/Subaru
Miss Caroline P. Wistar
A S U R V I V O R ’ S S T O RY
Rich and Ann Beston had a young son and another baby on the way when they
received the shocking news in February 2000 that Rich had stage IV melanoma.
He underwent several grueling surgeries, a clinical trial of an experimental
therapy, and chemotherapy with Ann at his side. During the course of Rich’s
treatment, Ann founded a melanoma support group and became connected with
the Noreen O’Neill Foundation for Melanoma Research.
Since then, they have become enthusiastic supporters of the foundation’s
annual Running for Cover race – and the Wistar research it funds. “We feel
good knowing the money is going directly to the scientists,” Ann says.
Qihong Huang, M.D., Ph.D., received the event’s 2007 proceeds, which
supported his research on genes that promote melanoma metastasis. “This
funding is crucial for my research,” he says, “especially with the federal research
budget so tight.”
Today, Rich shows no sign of melanoma. He’s feeling great and enjoying
life with Ann and their two children, Ryan and Shannon. “I feel so blessed just
to appreciate every moment with my family,” he says, “and fortunate that I can
help raise awareness about melanoma and the need for research.”
Melanoma survivor Rich Beston helps to raise awareness of the disease –
and funding to support research at Wistar.
ANNUAL REPORT 2007
25
ANNUAL G I V I N G continued
ASSOCIATES
($100 and over)
Mrs. Edith R. Ackerman
Mrs. Mary Rhoads Alexander
Ament Pool Service
Automobile Dealers Association of Greater
Philadelphia
Mr. and Mrs. Robert A. Bacine
Mrs. JoAnne S. Bagnell
Mrs. Eileen M. Baird
Mr. and Mrs. Frederic L. Ballard, Jr.
Charles J. Bauernschmidt, Esq.
Mr. James Beck
Mr. Paul Belanger
Mrs. Dene K. Bernstein
Mr. and Mrs. Howard Bleznak
Mr. and Mrs. Kenneth Boone
Mr. and Mrs. Martin Brait
Mr. and Mrs. Jack Bridges
Mr. Gary Bromberg
Dr. and Mrs. T. Wistar Brown V
Mr. and Mrs. Edward G. Bussinger
Mr. and Mrs. Robert B. Cahall
Mr. Jared Cannon
Mrs. Barbara Cantor
Mr. and Mrs. Howard M. Casper
Cherokee Construction Co.
Cichetti & Siegel Orthodontic Associates, Ltd.
Mr. and Mrs. Robert Hacker Clapham
Ms. Gwen A. Clendenning
Dr. Walter Cohen
Mr. and Mrs. Walter J. Conti
Ms. Julie Coryn and Mr. Austin Hyde
Mr. Steve Cotterman
Ms. Helen T. Davis
Mrs. Yvonne K. Davis
Miss Clara S. Deily
Mr. and Mrs. Samuel E. Dennis
Denville Scientific Products
Mr. and Mrs. William M. Deuber
Ms. Barbara DeWilde
Mr. Scott Dillman
Dover Volkswagen
Mrs. Louisa C. Dubin
Mr. Robert E. Dvorak
Mr. and Mrs. Edward Edelstein
Mr. Ted L. Edwards
Drs. Judith Wolf and Howard Eisen
Mr. and Mrs. Joseph S. Elmaleh
Mrs. Virginia Burt Eppinger
Mr. Sam Epstein
Ms. Susan M. Erda
Ms. Roni L. Feierstein
Drs. Norman and Helen Felsenthal
Dr. and Mrs. Robert M. Fisher
Ms. Anna Lois Flack
Ms. Jackie Flaherty
Mr. Richard L. Freundlich
Mr. and Mrs. Joseph H. Friedrich
GFW Enterprises
Ms. Judi Giberson-Smith
Mr. and Mrs. Henry A. Gladstone
Ms. Adrienne Gliba-Barrett
Mr. and Mrs. Marc Goldberg
Rose and Joan Goldberg
Ms. Beatrice Goldman
Ms. Jane E. Gulick
Mr. and Mrs. Gerald Gushner
26
ANNUAL REPORT 2007
Mr. and Mrs. Mark Gushner
Dr. Charles Hackett
Ms. Julia H. Hansbarger
Mr. and Mrs. Roy Harvey
Mr. and Mrs. Geoffrey Haynes
Ms. Bonnie Held
Dr. and Mrs. Scott H. Herbert
Mr. Steve Hladczuk
Mr. and Mrs. Norman Hockman
Mr. Franklin Hoke
Mr. and Mrs. David Holden
Mr. Charles R. Hooven
Ms. Anne Humes
Infiniti of Willow Grove
Ms. Anna M. Jackson
David A. and Constance Z. Jenkins
Mr. and Mrs. Jerry L. Johnson
Mr. Robert Johnson
Mr. Edward P. Kacer
Mr. and Mrs. Joseph M. Kalman
Mr. and Mrs. Jackson K. Kao
Mrs. Selma Katz
Mr. and Mrs. Ary L. Kaufmann
Mr. John J. Kelly, Jr.
Mr. and Mrs. Jeffrey M. Knetsch
Barbara B. Knowles, Ph.D.
Mr. and Mrs. Leonard I. Korman
Mr. and Mrs. Harvey S. Kronfeld
Mr. and Mrs. Robert A. Lagas
Mrs. Frances R. Lax
Mr. and Mrs. Ernest R. Leitenberger
Mr. and Mrs. Bernard Lemonick
Mr. and Mrs. Arnold Levin, Esq.
Dr. and Mrs. Elliot M. Levine
Ms. Bernice Linden
Ms. Susan Lindenbaum
Mr. and Mrs. Ed Lipski
John Loiselle, M.D., and Christine Reuther, Esq.
Ms. Anne S. Lynott
Mr. and Mrs. Patrick J. Lynott
Mr. and Mrs. Lee Maimon
Francine L. Marcus, M.D.
Mrs. Donald McDonald
Mr. and Mrs. Howard McPherson
Mercantile Bankshares Corporation
Dr. and Mrs. David Metz
Mr. and Mrs. Kurtis L. Meyer
Mr. Thomas A. Meyers and Dr. Barbara
Knight-Meyers
Mr. Robert A. Miller
Mr. William McElwee Miller, Jr.
Mr. and Mrs. Jack Moffat
Mrs. Samuel W. Morris
Ms. Ann R. Morton
Mr. and Mrs. Jack D. Moses
Dr. and Mrs. Steven J. Munzer
Sandya Narayanswami, Ph.D.
Rise P. Newman, Esq.
Ms. Elizabeth B. O’Brien and Mr. Philip Scott
Mrs. Arlene D. Odell
Mr. Robert D. Odell
Old York Road Sports Car Club
Ms. Mae O’Neill
Edward B. O’Reilly & Associates
Harold J. Pendergrass, Esq.
Mr. and Mrs. Roy T. Peraino
Ms. Gail Pesce and Ms. Virginia Haltmeier
Mr. and Mrs. David N. Pincus
Ms. Sherry R. Pirillo
Mrs. Alberta D. Proietta
Mr. and Mrs. Joseph Ramsay
Mr. and Mrs. David S. Randolph
Ms. Linda Recentio
Mr. and Mrs. Robert J. Reichlin
Mr. and Mrs. Stanley Reichlin
Ms. Carolyn Reinbold
Mr. Wayne D. Reynolds
Dr. Caroline S. Rhoads
Mr. Samuel Vail Rhoads
Mr. and Mrs. Richard M. Rosenbleeth
Mr. Abraham R. Rosenkrantz
Mr. and Mrs. Kevin Ross
Mr. and Mrs. Louis E. Rousso
Ms. Sue Goldstein Rubel
Mr. and Mrs. Howard I. Rubin
Dr. and Mrs. Karl F. Rugart, Jr.
Mr. and Mrs. Joseph P. Ryan, Jr.
Mr. George W. Samson
Mr. Terry Samway
Mr. and Mrs. Richard Schatz
Mr. Gustave Scheerbaum, III
Mrs. Jacqueline F. Schreider
Ms. Nora Pincus Schwarz
Mr. and Mrs. Michael A. Scully
Ms. Sonia Seifert
Gloria Marin Darthea Sharples, Ph.D.
Mr. Allan R. Shassian
Mr. and Mrs. Robert W. Shavelson
Mrs. Shirley Shils
Mr. Michael Shore
Ms. Leola V. Shumar
Dr. Steven Silber
Mr. and Mrs. Charles H. Silverman
Ms. Diana Slaymaker
Mr. and Mrs. Alan P. Smith
Mr. Richard D. Smith
Mrs. Loretta R. Spadea
Ms. Bonnie Squires and Mr. Sami Ouahada
Mr. Louis Starkman
Mr. Jacob Strauss
Mr. and Mrs. Samuel S. Stroud
Dr. Janine G. Tabas and Mr. Robert R. Tabas
Mrs. Jean M. Taxin
Mr. and Mrs. Edward Tepper
Thompson Toyota Scion
Mr. and Mrs. Andrew Thompson
Mr. James Burke and Ms. Georgine Tidmore
Mr. and Mrs. Philip Tigar
Dr. and Mrs. Lawrence W. C. Tom
Mrs. Betty F. Tomaselli
Mr. and Mrs. Merv Tuckman
United Way of Tri-State
VW Credit, Inc
Mrs. Kathleen L. Walker
Mr. and Mrs. Morton B. Wapner
Mrs. Helen B. Warner
Dr. and Mrs. Leonard Warren
Mr. and Mrs. John C. Weidman, Jr.
Dr. Alan J. and Mrs. Margaret Ann Weir
Mrs. Margaret W. Wellington
Mr. and Mrs. Raymond H. Welsh
Mr. Reggie Wilkes
Mr. and Mrs. Charles E. Will
Mr. and Mrs. Rob Wilson
Mr. Gil Wistar
Mrs. Veronica M. Wistar
Mr. George C. Wood
Mr. and Mrs. Morris Wistar Wood, Jr.
Mr. and Mrs. Alan B. Worthington
Mr. and Mrs. John B. Wright
Mrs. Suzanne R. Yusem
Mr. and Mrs. Bernard Zolot
IN
HONOR
OF
In honor of Susan Auerback’s 60th birthday
In honor of Mac Lerner’s 80th birthday
In honor of Clara Coan and Pat Knight
In honor of Billy Lovett’s birthday
In honor of Peter Corrado
Mr. Wayne D. Rowland and Ms. Denise DiPangrazio
In honor of Willie Mooney’s speedy recovery
In honor of Stephen Allen Cozen
Ms. E. K. Pomerantz and Mr. Leslie Miller
In honor of Tim and Elizabeth Pesce
Mr. and Mrs. Ed Lipski
In honor of Hal Davis
Mr. and Mrs. Sam S. McKeel
Ms. Maria Colelli
In honor of Mr. and Mrs. Wolfgang Puck’s wedding
Ms. Bernice Linden
In honor of Dr. and Mrs. Arthur Drazan’s 50th anniversary
In honor of Dr. Steve Fink’s speedy recovery
In honor of Ellen First’s 60th birthday
In honor of Mr. and Mrs. Barclay W. Fitzpatrick
Mr. and Mrs. Peter E. Corrado
In honor of Robert Fox’s speedy recovery
Mr. and Mrs. Leonard I. Korman
In honor of Bob Fox
Mr. Robert A. Miller
In honor of David and Helen Pudlin
Mr. and Mrs. William Mutterperl
In honor of David Rich’s 80th birthday
In honor of Marion Rocker
In honor of Ina Sue Ross’s speedy recovery
Mr. and Mrs. Barry Wolf
In honor of Ed Sickles
In honor of Albert W. Sheppard, Jr.’s speedy recovery
In honor of Johnnie Steven’s special birthday
Mr. and Mrs. Harold Schaeffer
In honor of Ben Frankel’s 75th birthday
In honor of Mr. and Mrs. Lewis Stone’s 50th anniversary
In honor of Bunny Glick-Shapiro’s 75th birthday
Mr. and Mrs. Andrew Ney
In honor of Lewis Stone’s special birthday
In honor of Mr. and Mrs. Jerry Gushner’s 55th wedding anniversary
In honor of Frances Tobin
In honor of Cathy Hart’s speedy recovery
In honor of Shirley Weisman’s special birthday
In honor of Leslie Isen’s father
In honor of David Wolfson’s bar mitzvah
In honor of Selma Katz’s 92nd birthday
Mrs. Jean M. Taxin
In honor of Peal Klemow’s speedy recovery
In honor of Carol and Harry Kutcher’s wedding
ANNUAL REPORT 2007
27
IN
MEMORY
OF
In memory of Alvin Ackerman
Mrs. Edith R. Ackerman
In memory of Fred Cohen
In memory of Elsa Alper
In memory of Miki Cohen
In memory of John Aposotola
In memory of Sandy Cohen
Mr. and Mrs. John Martino
In memory of Carol Barrett
In memory of Jessica Coleman
In memory of Judge Myrna Field Baum
In memory of F. Rogers Cooper
In memory of Harold Bellmuth
In memory of Vincent Cristofalo
Mr. and Mrs. Gary Blum
In memory of Louise Binswanger
In memory of Christopher Davis
Ms. Joyce C. Barrett
Mr. and Mrs. Richard H. Gwinn
In memory of Barbara Blessington
Mrs. Mae Taxin Brody
In memory of Kenneth Powell Blomerth
Ms. Janna Hardy
In memory of Bobby Blount's brother
In memory of Albert Sonny Borish
Mr. Louis Starkman
In memory of Is Brodsky
In memory of Charlotte
In memory of Warren Cheston
Mr. and Mrs. Kurtis L. Meyer
In memory of Edwin Clarke
In memory of Nickey Cohen
In memory of Joanne Durbin
Ms. Ann R. Morton
In memory of Annabelle Ambler Dvorak
Ms. Jane W. Deprado
Mr. Robert E. Dvorak
Mr. and Mrs. Richard Gerber
Mr. Edward P. Kacer
Ms. Jean D. Long
Mr. and Mrs. Howard McPherson
Ms. Dorothy Nicholson-Brown
Mr. Wayne D. Reynolds
Mr. Dan Rowlands
Ms. Gayle B. Watts
In memory of Stanley (Chicky) Feldman
Mrs. Jean M. Taxin
In memory of Mary Fenkel’s mother
In memory of Brad Fenton’s father
NOW
MORE THAN EVER
Donor support has never been more important to Wistar’s research, given the recent
decline in grant funding from the National Institutes of Health. The success rate of
first-time NIH grant applicants has dropped by 59 percent in the past eight years; only
12 percent were funded in 2007, compared to 29 percent in 1999.
28
ANNUAL REPORT 2007
In memory of Olga Goldstein
In memory of Delbert Johnson
Alpha Office Supplies
Mr. and Mrs. Kenneth Boone
Mr. James Brown
Mr. James A. Chafoulias
Mr. Ted L. Edwards
Mr. and Mrs. Jerry Johnson
Mr. Willie Johnson
Keystone Mercy Health Plan
Mercantile Bankshares Corporation
Merck & Co. Inc.
PRWT Services
Radnor Trust
Mr. Robert C. Schlotthauer
Bernard W. Smalley, Esq.
Mr. Reggie Wilkes
In memory of Harry Goodman
In memory of of Joy L. Kanter
Francine L. Marcus, M.D.
In memory of Laurence J. Hogan
Mr. R. Joseph Barnes
Mr. and Mrs. Joseph Cerino
Mr. Robert H. Quinn
In memory of Colonel Theodore Katz and Natalie Makler Katz
Ms. Sherry R. Pirillo
In memory of William Forbush
In memory of Gert Fox
In memory of Harry Ginsburg
In memory of Mrs. Arnold Glatter’s sister
In memory of Tyler Goldberg
In memory of Robert Holbert
Mr. and Mrs. K. Frederick Achenbach, Jr.
Ament Pool Service
Automobile Dealers Association of Greater Philadelphia
Mr. and Mrs. Stefan Bogdan
Mr. and Mrs. Jack Bridges
Ms. Carol Christine
Mr. and Mrs. Arthur Cohn
Mr. and Mrs. Walter J. Conti
Ms. Helen T. Davis
Dover Volkswagen
Edward B. O’Reilly & Associates
GFW Enterprises
Goldenberg Rosenthal LLP
Mr. and Mrs. David Holden
Infiniti of Willow Grove
Mr. Robert Johnson
Mr. William Kurz
Mr. and Mrs. Joseph S. La Rosa
Ms. Marianne Lanzetta Long
Mr. Samuel Longo
Mr. Ronald J. Lorch
Mr. and Mrs. Hugh McCloskey
Old York Road Sports Car Club
Ms. Doris Rafaeli
Ms. Linda Recentio
Riesentoter Region PCA
Mr. and Mrs. Thomas H. Ronan
Mr. and Mrs. William Schenck
Mr. and Mrs. Harry M. Stephey
Michael Stumpf & Associates, Inc
Thompson Toyota Scion
Mr. and Mrs. Glen Van Fossen
VW Credit, Inc
In memory of Ellis Ivker
Meryle J. Melnicoff, Ph.D.
In memory of Fred Jaron
Mr. and Mrs. C. Lawrence Rutstein
In memory of Bernie Kauffman
In memory of Sarah Kauffman
In memory of Judith Kenyon
In memory of Arthur Klein
Mr. and Mrs. Daniel E. Francis
Provincial Foundation
In memory of Walter Kristoff
In memory of Adolf Kurtzman
In memory of Joanne Leibovitz’s mother
In memory of Robert E. Leitenberger
Mr. and Mrs. Ernest R. Leitenberger
In memory of Marni Lindenbaum
Ms. Carol Crnobori
Mr. and Mrs. Marc Goldberg
Ms. Leni Goldsmith
Ms. Bonnie Held
In memory of Betty McCloskey
Mrs. Doris R. Taxin
In memory of Sylvia Meyers
Dr. and Mrs. Jerome I. Flicker
In memory of Albert Miller
Mrs. Jean M. Taxin
In memory of Selma Mones’ daughter
In memory of Samuel Needleman
ANNUAL REPORT 2007
29
IN
MEMORY
OF continued
In memory of Elaine M. Ominsky, Ph.D.
Mr. and Mrs. Leonard Dubin
Dr. and Mrs. David Metz
Mr. Abraham R. Rosenkrantz
Dr. Janine G. Tabas and Mr. Robert R. Tabas
Ms. Eunice Trevor
In memory of Shirley O’Neill
In memory of Diego Orgasan
In memory of Louis Oswald
In memory of Bernice Patlove
In memory of Eileen Patterson
In memory of Max Paul’s father
In memory of Elaine Phillips
In memory of Allan Portnov
In memory of Irv Rappoport
Mr. and Mrs. Leonard A. Jackowski
In memory of Anita Rubin
Mrs. Jean M. Taxin
In memory of Doris Samitz’s brother
In memory of Philip S. Seltzer
In memory of Erwin Sharps
In memory of Marion Stettler
Ms. Barbara DeWilde
In memory of Kattie Mae Stevens
Dr. and Mrs. Elliot M. Levine
In memory of Albert Taxin
Mrs. Loretta R. Spadea
In memory of Lawrence Timms
In memory of Richard James Tredinnick
In memory of Jim Walden
In memory of Louis C. Washburn
Bollinger
Ms. Margaret Gouzie
Ms. Anne Parkin Pierpoint
Ms. Gail Pesce and Ms. Virginia Haltmeier
Ms. Diana Slaymaker
Mr. and Mrs. Andrew Thompson
Mr. and Mrs. Philip Tigar
In memory of Ailsa Wistar
Mrs. Murray Belman
In memory of Heidi Schulz
In memory of Karen Yoh
In memory of Scott A. Schwartz, Jr.
In memory of Irene Ysenchak
Mr. James Burke and Ms. Georgine Tidmore
In memory of Ted Seidenberg
In memory of Matt Zamites’ mother
BRIDGING
THE
GAP
Donor contributions are especially critical to the work of young investigators.
Because of the recent decline in federal research funding, scientists are receiving
their first major governmental grants later in their careers. Private funding helps to
support young researchers – and launch innovative projects that otherwise might
never get off the ground.
30
ANNUAL REPORT 2007
SCIENTIFIC
STAFF
President and CEO
Russel E. Kaufman, M.D
Vice President for Academic Affairs
John J. Lucas, Ph.D.
Professor and Associate Vice President for
Academic Affairs
Ellen Puré, Ph.D.
Professor and Deputy Director of
The Wistar Institute Cancer Center
Frank J. Rauscher III, Ph.D.
Hilary Koprowski Professor
Shelley L. Berger, Ph.D.
RESEARCH PROGRAM:
GENE EXPRESSION AND REGULATION
Professors
Frank J. Rauscher III, Ph.D., Program Leader
Shelley L. Berger, Ph.D.
Paul M. Lieberman, Ph.D.
Ronen Marmorstein, Ph.D.
Gerd G. Maul, Ph.D.
Kazuko Nishikura, Ph.D.
Ramin Shiekhattar, Ph.D.
Associate Professors
Anthony J. Capobianco, Ph.D.
Jumin Zhou, Ph.D.2
Assistant Professors
Susan Janicki, Ph.D.
Ken-ichi Noma, Ph.D.
Emmanuel Skordalakes, Ph.D.
Staff Scientists
Zhong Deng, Ph.D.
Min Gyu Lee, Ph.D.
Dimitri Negorev, Ph.D.
Hongzhuang Peng, Ph.D.
Associate Staff Scientists
Qi Chen, M.D.
Jayaraju Dheekollu, Ph.D.
Jing Huang, Ph.D.
Thanuja Krishnamoorthy, Ph.D.
Fang Lu, Ph.D.
Yong Tang, Ph.D.
Pu Wang, Ph.D.
Jing Zhou, Ph.D.
RESEARCH PROGRAM:
IMMUNOLOGY
Professors
Hildegund C.J. Ertl, M.D., Program Leader
Andrew J. Caton, Ph.D.
Jan Erikson, Ph.D.
Walter Gerhard, M.D.3
Dorothee Herlyn, D.V.M.
Luis J. Montaner, D.V.M., D.Phil.
Ellen Puré, Ph.D.1
Hui Hu, Ph.D.
Wolfgang Weninger, M.D.4
E. John Wherry, Ph.D.
Senior Staff Scientists
Livio Azzoni, M.D., Ph.D.
Jihed Chehimi, Ph.D.
Rajasekharan Somasundaran, Ph.D.
Rolf Swoboda, Ph.D.
Zhi Quan Xiang, M.D.
Xiang Yang Zhou, Ph.D.
Staff Scientists
Emmanouil Papasavvas, Ph.D.
Dongming Zhou, Ph.D.
Nadeem Ali-Khan, Ph.D.
Brian Hondowicz, Ph.D.
Marcio Lasaro, Ph.D.
Hua Li, M.D.
RESEARCH PROGRAM:
MOLECULAR AND CELLULAR ONCOGENESIS
Cancer Biology Division
Professors
Meenhard Herlyn, D.V.M., Program Co-leader
Dorothee Herlyn, D.V.M.1
Nadia Dahmane, Ph.D.
Joseph Kissil, Ph.D.
Keiran Smalley, Ph.D.
Mingyuan Zhou, Ph.D.
Staff Scientists
Mizuho Kalabis, Ph.D.
Hsin-Yao Tang, Ph.D.
Tao Wang, M.D., Ph.D.
Tianqian Zhang, Ph.D.
Valerie Baubet, Ph.D.
Systems Biology Division
Professors
David W. Speicher, Ph.D., Program Co-leader
Ellen Heber-Katz, Ph.D.
Ellen Puré, Ph.D.
Ramin Shiekhattar, Ph.D.1
Louise C. Showe, Ph.D.
Harold C. Riethman, Ph.D.
Qihong Huang, M.D., Ph.D.
Carlton C. Maley, Ph.D.
Michael Showe, Ph.D.
Staff Scientists
Lise Clark, D.V.M., Ph.D.
Kiranmai Gumireddy, Ph.D.
Michele Jacob, Ph.D.
Elena Nikonova, M.D.
Celia Chang, M.D.
Dmitri Gourevitch, M.D.
Linda Hanlon, Ph.D.
Paulus Mrass, M.D.
SHARED FACILITY DIRECTORS
Ping Jiang, Ph.D.
John Rux, Ph.D.
David Schultz, Ph.D.
Professor Laureate
Professors Emeriti
Clayton A. Buck, Ph.D.
Roger M. Burnett, Ph.D.
Walter Gerhard, M.D.5
Elliot M. Levine, Ph.D.6
Stanley A. Plotkin, M.D.
Robert Roosa, Ph.D.
Leonard Warren, M.D., Ph.D.
Zofia Wroblewska, M.D.
1 Secondary appointment
2 Promoted to associate professor January 1, 2008
3 Retired September 1, 2007
4 Appointment ended May 4, 2007
5 Effective September 1, 2007
6 Effective January 1, 2008
ANNUAL REPORT 2007
31
SCIENTIFIC
STAFF continued
ADJUNCT FACULTY
Professors
Stephen M. Albelda, M.D.
University of Pennsylvania
Richard Assoian, Ph.D.
Timothy M. Block, Ph.D.
Drexel University
Garret M. Brodeur, M.D.
H. Fred Clark, D.V.M., Ph.D.
Dennis E. Discher, Ph.D.
Chaitanya R. Divgi, M.D.
Wafik S. El-Deiry, M.D., Ph.D.
David E. Elder, M.B., Ch.B.
Beverly S. Emanuel, Ph.D.
Nigel W. Fraser, Ph.D.
Mark I. Greene, M.D., Ph.D.
Thanos Halazonetis, D.D.S., Ph.D.
University of Geneva
Katherine S. High, M.D.
Paul A. Offit, M.D.
Reynold Panettieri, M.D.
George C. Prendergast, M.D.
Lankenau Institute for Medical Research
Thomas D. Stamato, Ph.D.
Lankenau Institute for Medical Research
James M. Wilson, M.D., Ph.D.
John H. Wolfe, V.M.D., Ph.D.
Wolfgang Weninger, Ph.D.
University of Sydney
Horace M. DeLisser, M.D.
ADMINISTRATIVE
Phyllis A. Gimotty, Ph.D.
President and CEO
Ann K. Jeglum, V.M.D.
Veterinary Oncology Services and Research Center
Larry A. Keinath, C.P.A.
Vice President for Finance and Administration
Steve McMahon, Ph.D.
Thomas Jefferson University
Elizabeth O’Brien, Esq.
Vice President for Legal and External Affairs
Laszlo Otvos Jr., Ph.D.
Temple University
John J. Lucas, Ph.D.
Vice President for Academic Affairs
Omaida Velaquez, M.D.
Ellen Puré, Ph.D.
Professor and Associate Vice President for Academic Affairs
Michael Betts, Ph.D.
Frank J. Rauscher III, Ph.D.
Professor and Deputy Director of The Wistar Institute
Cancer Center
Keith T. Flaherty, M.D.
Peter Corrado
Director of Institutional Development
Mark S. Lechner, Ph.D.
Drexel University
Denise DiFrancesco
Director of Animal Facility
Eric Meggers, Ph.D.
Abbey J. Porter
Acting Director of Public Relations
EXTERNAL SCIENTIFIC ADVISORY COMMITTEE
Van Cherington, Ph.D.
Director of Science Administration
Chair
Edward Ziff, Ph.D.1
New York University Medical Center
Nina Long, M.L.S.
Director of Library Services and Curator of
The Wistar Museum Collections
Members
Riccardo Dalla-Favera, M.D.2
Irving Comprehensive Research Center
Ronen Marmorstein, Ph.D.
Director of Training
Olivera J. Finn, Ph.D.
University of Pittsburgh
Todd R. Golub, M.D.
The Broad Institute of MIT and Harvard
Peter E. Lipsky, M.D.
National Institute of Arthritis and Musculoskeletal and
Skin Diseases
Lynn M. Matrisian, Ph.D.
Vanderbilt University
Joseph S. Pagano, M.D.
University of North Carolina Lineberger Comprehensive
Cancer Center
Hidde Ploegh, Ph.D.
Whitehead Institute for Biomedical Research
Danny Reinberg, Ph.D.1
Smilow Research Center,
New York University School of Medicine
Richard A. Young, Ph.D.
Whitehead Institute for Biomedical Research
1 Effective March 2008
2 Effective April 2008
32
ANNUAL REPORT 2007
STAFF
Meryle J. Melnicoff, Ph.D.
Director of Business Development
Jo-Ann Mendel
Director of Human Resources
Marianne O’Neill
Director of Grants and Contracts Administration
Ray Preis
Director of Information Systems
Kenneth J. Sulkowski
Director of Facilities
Stephen E. Tustin, C.P.A.
Director of Finance
Willian H. Wunner, Ph.D.
Director of Outreach Education and Technology Training
112798W1
6/2/08
2:27 PM
Page 38
VOLUNTEER
LEADERSHIP
BOARD OF TRUSTEES
Professor
Thomas Jefferson University
Professor Laureate
The Wistar Institute
EMERITUS MEMBERS
Brian H. Dovey
Chair
Faye Olivieri Kozich
Harold M. Davis
Co-Vice Chair
Ira M. Lubert1
Lubert-Adler Management, Inc.
Peter C. Doherty, Ph.D.
Nobel Laureate
Chairman, Department of Immunology
St. Jude Children’s Research Hospital
Helen P. Pudlin, Esq.
Co-Vice Chair
Dan W. Matthias
CEO
Mothers Work
OFFICERS
Doris Taxin
Secretary
Ian J. Berg
Treasurer
Albert Ominsky, Esq.
Ominsky and Ominsky, P.C.
Vincent G. Bell, Jr.
President
Verus Corporation
Jean Bellet Green
Harris N. Hollin
President
Conquer Fragile X Foundation
Isadore M. Scott
Ruth Patrick, Ph.D.
Francis Boyer Chair
The Academy of Natural Sciences
MEMBERS
Ian J. Berg
Managing Director
ETF Venture Funds
Robert S. Blank
Partner
Whitcom Partners
Dani P. Bolognesi, Ph.D.
Chairman and CEO
B3Bio, Inc.
Ira Brind
President
Brind Investments, Inc.
Ronald J. Daniels
Provost
Harold M. Davis
Chairman
Realen Properties
Seymour S. Preston, III
The Millrace Group
1 Resigned March 2008
Helen P. Pudlin, Esq.
Senior Vice President and General Counsel
Samuel V. Rhoads
Senior Vice President
Philadelphia Industrial Development Corp.
Robert H. Rock
President
MLR Holdings, LLC
Gerald B. Rorer
LEADERSHIP COUNCIL
Max Berger
MBA Equities, Ltd.
Eric Bernstein, M.D.
Main Line Center for Laser Surgery
Arnon Dreyfuss, M.D.
Adele K. Schaeffer
Joseph A. Goldblum
Goldblum Hess
Paul J. Schmitt
Managing Director
Novitas Capital
Scott H. Herbert, M.D.
The Rosenfeld Cancer Center
Abington Memorial Hospital
Edward Sickles
Richard M. Horowitz
RAF Industries Inc.
Brian H. Dovey
General Partner
Domain Associates
Judith E. Soltz
Robert A. Fox
Chairman and CEO
R.A.F. Industries, Inc.
Susan R. Sullivan1
Roger S. Hillas
Kevin M. Tucker
Patrick M. Oates, Ph.D.
Wyeth Pharmaceuticals
Richard M. Horowitz
President
R.A.F. Industries, Inc.
George J. Vergis, Ph.D.
President and CEO
Neose Technologies, Inc.
Elizabeth A. Pesce
Beco-Designs
Herbert Kean, M.D.
David V. Wachs
Kenneth S. Resnik, M.D.
Institute for Dermopathology
Arthur L. Stokes, M.D.
Doris Taxin
Daniel H. Wheeler
Sharon Kestenbaum
Fishman & Tobin
Susan Schwartz McDonald, Ph.D.
National Analysts
Jim Schaeffer
Ruby’s of Pennsylvania
Aubrey Watkins
Merck & Company
TODAY’S
DISCOVERIES
TOMORROW’S
CURES
3601 Spruce Street
Philadelphia, PA 19104-4265
215-898-3700
www.wistar.org
The Wistar Institute’s 2007 Annual Report was produced by the
Office of Public Relations.
Abbey J. Porter, Acting Director of Public Relations
Lee Christine Shurtz, Public Relations Assistant
Writing: Thomas W. Durso
Design: SK Designworks, Inc.
Photography: Tommy Leonardi
Supplemental Photography: James E. Hayden, Frederick S. Keeney
and Peter Olson
Stock Photography: Corbis, iStockphoto and Media Bakery
The Wistar Institute is an equal opportunity/affirmative action
employer. It is the policy of The Wistar Institute to provide equal
employment opportunities to all individuals regardless of race, color,
creed, religion, national origin, ancestry, sex, age, veteran status,
disability, sexual orientation, or gender identity for all terms and
conditions of employment.
Published June 2008

2007 Annual Report - The Wistar Institute

Transcription

Similar documents

File

Mrs. Starr`s Second Grade Class loves going to the computer lab

May 18, 2012 - Urbana City Schools

Funeral Services For Mrs. Jennie Thompson are rteld

BOSSLey Biz - Bossley Park High School

mrs. flutterbee`s music and movement assemblies

Welcome to Year 9 2015

2010 Part 2

15-16_COVMS_Newsletter_Sep

CNTEAEDITION2Newsletter - Colts Neck Township Education